Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of relugolix combination tablets for heavy menstrual bleeding associated with uterine fibroids
CTR20253621Phase 3Active
- Sponsor
- Chengdu Brilliant Pharmaceutical Co., Ltd.
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tissue-plasminogen activator, medroxyprogesterone acetate, estradiol valerate in Fibromyoma (LM), sponsored by Chengdu Brilliant Pharmaceutical Co., Ltd.. Started Jan 2026; status: active.
02
Drugs
tissue-plasminogen activatormedroxyprogesterone acetateestradiol valerate
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on CTR20253621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253621.